Replies to post #644 on NuPathe Inc (fka PATH) (PATH)

[surf1944]

7:01AM NuPathe announces allowance of additional U.S. patent for ZECUITY (PATH) 2.59 : Co announced that the USPTO has issued a notice of allowance for U.S. Patent application 13/407,434. This application relates to NuPathe's innovative iontophoretic patch that uses a two-stage delivery sequence to transdermally deliver sumatriptan. This, and other proprietary technology, is incorporated into NuPathe's lead product, ZECUITY (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch for migraine. Given this action, co expects the patent to issue within the next few months. Once issued, the patent will provide additional protection for ZECUITY and will be the sixth patent listed in the FDA's Orange Book. NuPathe has additional U.S. patents covering ZECUITY that expire between 2027 and 2029 and patent applications pending in the U.S. and other territories.